Aromatic liver X-receptor modulators

Abstract

The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.

Description

BACKGROUND

[0002] Liver X-receptors (LXRs) are nuclear receptors that regulate the metabolism of several important lipids, including cholesterol and bile acids. Most of the cholesterol in plasma is transported on three major lipoprotein classes; VLDL cholesterol (VLDL-C), LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C). Total cholesterol is the sum of all three lipoproteins. Both VLDL-C and LDL-C are associated with atherogenic processes while HDL-C is believed to facilitate cholesterol removal from tissues (e.g. atherosclerotic plaques) and thus have a protective effect on coronary heart disease.

[0003] LXR represents a novel intervention point to regulate the reverse cholesterol transport (RCT) pathway, i.e., the removal of cholesterol from peripheral tissues/cells and subsequent uptake via the liver for disposal. Removal of cellular cholesterol requires active transport of free cholesterol across the plasma membrane and onto HDL particles. This transfer of cholesterol from inside the cell and onto HDL in the plasma is mediated by ATP binding cassette 1 (ABCA1) transporter protein. The observation that LXR is a key transcriptional activator of ABCA1 in the macrophage, suggests that induction of LXR will lead to an increase in cholesterol efflux from the macrophage. In addition, it is known that LXR regulates the induction of other genes involved in RCT such as apoE and cholesterol ester transport protein (CETP), suggesting that activating the LXR pathway should also lead to increased uptake of cholesterol by the liver. Thus, activation of LXR by a small molecule ligand will lead to an up-regulation of ABCA1 and induction of the reverse cholesterol transport pathway thereby increasing cholesterol efflux to HDL-C and reducing the cholesterol content of atherosclerotic plaques.

SUMMARY OF THE INVENTION

[0004] In general, the present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and the isomers, tautomers, salts and prodrugs thereof: 1

[0005] wherein:

[0006] the X ring and the M ring are independently aromatic rings;

[0007] A is oxygen, sulfur, sulfoxide, sulfone, —NHC(═A2)— or —C(═A2)NH—;

[0008] A2 is oxygen or sulfur;

[0009] M1, M2, M3, M4, and M5 are independently a bond, carbon, nitrogen, oxygen or sulfur, provided, however, no more than one of M1, M2, M3, M4, and M5 is a bond;

[0010] M34 and M35 are independently an electron pair, hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxy, hydrocarbyloxy, substituted hydrocarbyloxy, mercapto, halo, heterocyclo, cyano, nitro, amino, acyloxy, or acyl, or M34 and M35 are bonded to adjacent carbon atoms and together with the atoms to which they are bonded form a fused ring system;

[0011] M40 is carbon, sulfur or sulfoxide;

[0012] M41 is oxygen, sulfur, or NM42;

[0013] M42 is hydrogen, hydrocarbyl, or substituted hydrocarbyl; and

[0014] M43 is hydrogen, hydrocarbyl, substituted hydrocarbyl, hydrocarbyloxy, substituted hydrocarbyloxy, amino, hydrocarbylthio, or substituted hydrocarbylthio;

[0015] p and q are independently 0, 1,or 2;

[0016] X1, X2, X3, and X4 are independently a bond, carbon, nitrogen, oxygen or sulfur, provided, however, no more than one of X1, X2, X3, and X4 is a bond;

[0017] X11, X22, X33, and X44, are independently an electron pair, hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxy, hydrocarbyloxy, substituted hydrocarbyloxy, mercapto, halo, heterocyclo, cyano, nitro, amino, acyloxy, or acyl; provided, however, X11, X22, X33, or X44 is not present when X1, X2, X3 or X4, respectively, is a bond;

[0018] X50 is carbon, sulfur or sulfoxide,

[0019] X51 is oxygen, sulfur, or NX52,

[0020] X52 is hydrogen, hydrocarbyl, or substituted hydrocarbyl; and

[0021] X53 is hydrogen, hydrocarbyl, substituted hydrocarbyl, heterocyclo, or amino.

[0022] The present invention is further directed to a process of treating a condition in a mammal that is modulated by LXR. The process comprises administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula I.

[0023] Other aspects of the invention will be in part apparent and in part pointed out hereinafter.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] In general, the present invention is directed to small molecule compounds corresponding to Formula I and the isomers, tautomers, salts and prodrugs thereof and their use as LXR modulators.

[0025] In one embodiment, the X ring and the M ring of Formula I are independently a six membered aromatic ring such as a benzene, pyridine or pyrimidine ring, or a 5-membered heteroaromatic ring such as a furan, thiophene, oxazole, pyrazole, pyrrole, thiazole, imidazole or isoxazole ring. For example, the X ring may be a 5-membered ring and the M ring may be a 6-membered ring, or vice versa.

[0026] As depicted in Formula I, the bridge between the X and the M rings is —(CH2)p—A—(CH2)q— wherein p, q, and A are as defined in connection with Formula I. In one embodiment, the sum of p and q does not exceed 2. In another embodiment, the sum of p and q is 1; for example, p may be 0 when q is 1. In each of these separate embodiments, A may be sulfur, sulfoxide, sulfone, —NHC(═A2)— or —C(═A2)NH— wherein A2 is oxygen or sulfur. In one particular embodiment, the sum of p and q is 1 and A is sulfur. For example, in this particular embodiment, the LXR modulator may correspond to Formula IIA or Formula IIB: 2

[0027] wherein the X ring and the M ring are independently aromatic rings and M1, M2, M3, M4, M5, M34, M35, M40, M41, M43, X1, X2, X3, X4, X11, X22, X33, X44, X50, X51, X52, and X53 are as defined in connection with Formula I.

[0028] In a further embodiment, the LXR modulators correspond to Formula IIA or IIB wherein the X ring and the M ring are independently benzene rings. In this embodiment, for example, the compounds correspond to Formula IIIA or IIIB: 3

[0029] wherein A, X11, X22, X33, X44, X50, X51, X53, M34, M35 M40, M41 and M43 are as defined in connection with Formula I. In one embodiment in which the LXR modulators correspond to Formula IIIA or IIIB, X50 is carbon and X51 is oxygen. In another embodiment in which the LXR modulators correspond to Formula IIIA or IIIB, X53 is heterocyclo, optionally substituted alkyl, or optionally substituted phenyl. In a further embodiment in which the compounds correspond to Formula IIIA or IIIB, X50 is carbon, X51 is oxygen and X53 is heterocyclo, optionally substituted alkyl, or optionally substituted phenyl. For example, in each of these separate embodiments, X53 may be heterocyclo (such as thienyl, pyridyl, piperidinyl, piperazinyl, or 2-oxabicyclo[2.2.1]heptane), linear or branched alkyl (such as methyl, t-butyl, isopropyl, or isobutyl), substituted alkyl (such as trichloromethyl, trifluoromethyl, (CH2Cl)(CH3)2C—, (CH3C(O)OCH2)(CH3)2C—, or (CH2OH)(CH3)2C—, cycloalkyl (such as cyclohexyl, cyclopentyl, adamantyl, or methylcyclohexane), phenyl, or substituted phenyl (such as 3-chlorophenyl or methoxyphenyl). In addition, in each of the embodiments in which the compounds correspond to Formula IIIA or IIIB, one of X11, X22, X33, and X44 may optionally be hydrogen, alkyl (such as methyl), nitro, or halo (such as chloro or fluoro) while the remainder of X11, X22, X33, X44 are hydrogen. In addition, in each of the embodiments in which the LXR modulators correspond to Formula IIIA or IIIB, M34 and M35 may optionally and independently be selected from hydrogen, alkoxy (such as methoxy), optionally substituted alkyl, or they may be attached to adjacent carbon atoms and, in combination with the carbon atoms to which they are attached, form a fused ring.

[0030] In a further embodiment, the LXR modulators correspond to Formula IV: 4

[0031] wherein:

[0032] p and q are independently 0, 1, or 2;

[0033] M17 is hydrogen, hydrocarbyl, substituted hydrocarbyl, hydrocarbyloxy, heterocyclo, amino, or acyl;

[0034] M18 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo;

[0035] M34 and M35 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, amino, alkoxy, halogen, or nitro;

[0036] X25 and X26 are independently hydrogen, optionally substituted alkyl, nitro or halo, and

[0037] X53 is hydrocarbyl, substituted hydrocarbyl or heterocyclo.

[0038] In one embodiment in which the LXR modulators correspond to Formula IV, the sum of p and q is one. In another embodiment in which the LXR modulators correspond to Formula IV, p is zero and q is one. In a further embodiment in which the LXR modulators correspond to Formula IV, p is one and q is zero. In each of these separate embodiments in which the LXR modulators correspond to Formula IV, X25, X26, X53, M17, M18, M34 and M35 are as defined in connection with Formula IV. For example, in each of these separate embodiments in which the compounds correspond to Formula IV, X53 may be heterocyclo such as thienyl, pyridyl, piperidinyl, piperazinyl, or 2-oxabicyclo-[2.2.1]heptane, linear or branched alkyl such as methyl, t-butyl, isopropyl, or isobutyl, substituted alkyl such as trichloromethyl, trifluoromethyl, (CH2Cl)(CH3)2C—, (CH3C(O)OCH2)(CH3)2C—, or (CH2OH)(CH3)2C—, cycloalkyl such as cyclohexyl, cyclopentyl, adamantyl, or methylcyclohexane, phenyl, or substituted phenyl such as 3-chlorophenyl or methoxyphenyl. In addition, in each of these separate embodiments, one of X25, and X26 is optionally alkyl (such as methyl), nitro, or halo (such as chloro or fluoro) while the remainder of X11, X22, X33, X44 are hydrogen. In addition, in each of these separate embodiments, M34 and M35 are independently optionally hydroxy, alkoxy, thioalkyl, hydrocarbyl or substituted hydrocarbyl.

[0039] In an alternative embodiment in which the LXR modulator corresponds to any of Formulae I, IIA, IIB, IIIA, IIIB, or IV, one of M17 and M18 contain a benzene ring or a heteroaromatic moiety. In this embodiment, for example, the LXR modulator may correspond to Formula V: 5

[0040] wherein:

[0041] the X ring, the M ring and the Y ring are aromatic;

[0042] Y1, Y2, Y3, Y4, and Y5 are independently a bond, carbon, nitrogen, oxygen or sulfur, provided, however, no more than one of Y1, Y2, Y3, Y4 and Y5 is a bond;

[0043] Y11, Y22, Y33, Y44, and Y55 are independently an electron pair, hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxy, hydrocarbyloxy, substituted hydrocarbyloxy, mercapto, halo, heterocyclo, cyano, nitro, amino, acyloxy, or acyl; provided, however, Y11, Y22, Y33, Y44 or Y55 is not present when Y1, Y2, Y3 Y4, or Y5, respectively, is a bond;

[0044] A, M1, M2, M3, M4, M5, M20, M34, M35, p, q, X1, X2, X3, X4, X11, X22, X33, X44, X50, X51, X52, and X53 are as defined in connection with Formula I,

[0045] M19 is a bond, hydrocarbyl or substituted hydrocarbyl, and

[0046] M20 is hydrogen, hydrocarbyl or substituted hydrocarbyl.

[0047] In yet another embodiment, the present invention is directed to compounds corresponding to Formula VI: 6

[0048] wherein:

[0049] the sum of p and q is 1,

[0050] M34, M35, and X53 are as defined in connection with Formula I;

[0051] M19, M20, Y1, Y2, Y3, Y4, Y5, Y11, Y22, Y33, Y44, and Y55 are as defined in connection with Formula V; and

[0052] X25 and X26 are independently hydrogen, optionally substituted alkyl, nitro or halo.

[0053] In one embodiment in which the LXR modulators correspond to Formula VI, Y11, Y22, Y33, Y44, and Y55 are independently an electron pair, hydrogen, hydrocarbyl, heterosubstituted hydrocarbyl, hydroxy, hydrocarbyloxy, substituted hydrocarbyloxy, mercapto, halo, heterocyclo, cyano, nitro, amino, aminoacyl, thioacyl, acyloxy, or acyl or any adjacent two of Y11, Y22, Y33, Y44, and Y55 together with the atoms to which they are bonded may comprise a fused ring system.

[0054] In an alternative embodiment in which the LXR modulator corresponds to any of Formulae I, IIA, IIB, IIIA, IIIB, or IV, M17 and M18 together with the nitrogen atom to which they are attached form a heterocylo. In this embodiment, for example, the LXR modulator corresponds to Formula VII: 7

[0055] wherein:

[0056] the X ring and the M ring are independently aromatic rings;

[0057] A, M1, M2, M3, M4, M5, M6, M34, M35, p, q, X1, X2, X3, X4, X11, X22, X33, X44, X50, X51, X52, and X53 are as defined in connection with Formula I; and

[0058] M21 in combination with the nitrogen atom to which it is bonded is heterocyclo.

[0059] In a further embodiment the LXR modulators correspond to Formula VIII: 8

[0060] wherein

[0061] X25 and X26 are independently hydrogen, optionally substituted alkyl, nitro or halo;

[0062] p, q, M34, M35, X53 are as defined in connection with Formula I; and

[0063] M21 is as defined in connection with Formula VII.

[0064] In one embodiment in which the LXR modulators correspond to Formula VIII, the sum of p and q is 1. For example, p may be 0 and q may be 1. Alternatively, p may be 1 and q may be 0. In addition, in each of these embodiments, the heterocycle comprising M20 may be further substituted by

[0065] M19-Y wherein M19 and Y are as defined in connection with Formula VI.

[0066] In a further embodiment the LXR modulators correspond to Formula IX: 9

[0067] Wherein:

[0068] X25 and X26 are independently hydrogen, optionally substituted alkyl, nitro or halo;

[0069] p, q, M34, M35, X53 are as defined in connection with Formula l; and

[0070] M40 is hydrocarbyl or substituted hydrocarbyl.

[0071] In one embodiment in which the LXR modulators correspond to Formula IX, the sum of p and q is 1. For example, p may be 0 and q may be 1. Alternatively, p may be 1 and q may be 0. In addition, in each of these embodiments, M40 may be alkyl or aryl.

[0072] Another aspect of the present invention are the prodrugs of the compounds corresponding to the formulae disclosed herein, which are converted under physiological conditions to the biologically active drug by any of a number of chemical and biological mechanisms. In general terms, these prodrug conversion mechanisms are hydrolysis, reduction, oxidation, and elimination.

[0073] A further aspect of the invention encompasses conversion of the prodrug to the biologically active drug by elimination of the prodrug moiety. Generally speaking, in this embodiment the prodrug moiety is removed under physiological conditions with a chemical or biological reaction. The elimination results in removal of the prodrug moiety and liberation of the biologically active drug. Any compound of the present invention corresponding to any of the formulas disclosed herein may undergo any combination of the above detailed mechanisms to convert the prodrug to the biologically active compound. For example, a particular compound may undergo hydrolysis, oxidation, elimination, and reduction to convert the prodrug to the biologically active compound. Equally, a particular compound may undergo only one of these mechanisms to convert the prodrug to the biologically active compound.

[0074] The compounds of the present invention can exist in tautomeric, geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis- and trans-geometric isomers, E- and Z-geometric isomers, R- and S-enantiomers, diastereomers, d-isomers, I-isomers, the racemic mixtures thereof and other mixtures thereof, as falling within the scope of any of the formulae disclosed herein. The terms “cis” and “trans”, as used herein, denote a form of geometric isomerism in which two carbon atoms connected by a double bond will each have a hydrogen atom on the same side of the double bond (“cis”) or on opposite sides of the double bond (“trans”). Some of the compounds described contain alkenyl groups, and are meant to include both cis and trans or “E” and “Z” geometric forms. Furthermore, some of the compounds described contain one or more stereocenters and are meant to include R, S, and mixtures or R and S forms for each stereocenter present.

[0075] Also included in the present invention are the pharmaceutically acceptable salts of any compound having corresponding to any of the formulas disclosed herein and the isomers, tautomers, and prodrugs thereof. The term “pharmaceutically-acceptable salt” includes commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of the compounds may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucoronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethylsulfonic, benzenesulfonic, sulfanilic, stearic, cyclohexylaminosulfonic, algenic, and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of the compounds include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N′-dibenzylethyleneldiamine, choline, chloroprocaine, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procain. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the selected compound of any of the formulae disclosed herein or the prodrug, isomer, or tautomer thereof.

[0076] The present invention also comprises a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention in association with at least one pharmaceutically acceptable carrier, adjuvant or diluent. Pharmaceutical compositions of the present invention can comprise the active compounds of any of the formulae disclosed herein or the prodrug, isomer, tautomer or prodrug thereof in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as “carrier” materials) and, if desired, other active ingredients. The compostions of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.

[0077] Synthesis

[0078] As depicted in Scheme 1, compounds of the present invention can be prepared by alkylation of (i) to give amine (iii) which can undergo acylation with an acid chloride or anhydride to give the target compounds (iv). Hydrolysis followed by amine coupling give the desired product (v). Additional compounds of the present invention can be prepared as in Scheme 2. Hydrolysis of the compound from Scheme 1 (iii) followed by amine coupling affords the amide (vi). Acylation of this compound gives the desired product (vii). Other compounds of the present invention can be prepared as in Scheme 3. Coupling of the amine with acid (ix) gives amide (x). Alkylation affords the nitro compound (xi). Reduction followed by acylation gives the target compounds (xiii). Additionally sulfides (A1═S) can be oxidized to the corresponding sulfoxides (A1═SO) and sulfones (A1═SO2). 1011

[0079] Other compounds of the present invention can be prepared by amine coupling to acid (ix) to form (x) followed by alkylation to yield (xi) (Scheme 3). The nitro group can be reduced to give amine (xii) and subsequent acylation to afford (xiii). 12

[0080] Administration

[0081] The LXR modulators useful in the practice of the present invention can be formulated into pharmaceutical compositions and administered by any means that will deliver a therapeutically effective dose. Such compositions can be administered orally, parenterally, intranasally, by inhalation spray, rectally, intradermally, transdermally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa. (1975), and Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y. (1980).

[0082] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, and polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

[0083] Suppositories for rectal administration of the compounds discussed herein can be prepared by mixing the active agent with a suitable non-irritating excipient such as cocoa butter, synthetic mono-, di-, or triglycerides, fatty acids, or polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature, and which will therefore melt in the rectum and release the drug.

[0084] Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the compounds can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, or magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

[0085] For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.

[0086] Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

[0087] The amount of active ingredient that can be combined with the carrier materials to produce a single dosage of the LXR modulator will vary depending upon the patient and the particular mode of administration. In general, the pharmaceutical compositions may contain a LXR modulator in the range of about 1 and 2500 mg, more typically, in the range of about 5 and 1000 mg and still more typically, between about 10 and 500 mg. A daily dose of about 0.1 to 50 mg/kg body weight, or more typically, between about 0.1 and about 25 mg/kg body weight and even more typically, from about 0.5 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to about four doses per day. Those skilled in the art will appreciate that dosages may also be determined with guidance from Goodman & Goldman's The Pharmacological Basis of Therapeutics, Ninth Edition (1996), Appendix II, pp. 1707-1711 and from Goodman & Goldman's The Pharmacological Basis of Therapeutics, Tenth Edition (2001), Appendix II, pp. 475-493.

[0088] Definitions

[0089] The term “acyl,” as used herein alone or as part of another group, denotes the moiety formed by removal of the hydroxyl group from the —COOH group of an organic carboxylic acid, e.g., RC(O)— wherein R is Ra, RaO—, RaS—, or RaRbN—, Ra and Rb are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or heterocyclo and “—” is the point of attachment.

[0090] The term “acylamino,” as used herein alone or as part of another group, denotes an acyl group as defined above, bonded through a nitrogen atom, e.g., RC(O)N(Rc)— wherein R is as defined in connection with the term “acyl”, Rc is hydrogen, hyrocarbyl, or substituted hydrocarbyl, and “—” denotes the point of attachment.

[0091] The term “acyloxy” as used herein alone or as part of another group, denotes an acyl group as defined above, bonded through an oxygen atom

[0092] (—O—), e.g., RC(O)O— wherein R is as defined in connection with the term “acyl” and “—” denotes the point of attachment.

[0093] The term “acylthio” as used herein alone or as part of another group, denotes an acyl group as defined above, bonded through a sulfur atom (—S—), e.g., RC(O)S— wherein R is as defined in connection with the term “acyl” and “—” denotes the point of attachment.

[0094] The term “amino” as used herein alone or as part of another group shall denote a primary, secondary or tertiary amine which may optionally be hydrocarbyl, substituted hydrocarbyl or heteroatom substituted. Specifically included are secondary or tertiary amine nitrogens which are members of a heterocyclic ring. Also specifically included, for example, are secondary or tertiary amino groups substituted by an acyl moiety.

[0095] Unless otherwise indicated, the alkyl groups described herein are preferably lower alkyl containing from one to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include methyl, ethyl, propyl, isopropyl, butyl, hexyl and the like.

[0096] Unless otherwise indicated, the alkenyl groups described herein are preferably lower alkenyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain or cyclic and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, and the like.

[0097] Unless otherwise indicated, the alkynyl groups described herein are preferably lower alkynyl containing from two to eight carbon atoms in the principal chain and up to 20 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, hexynyl, and the like.

[0098] The term “aromatic” shall mean aryl or heteroaromatic.

[0099] The terms “aryl” or “ar” as used herein alone or as part of another group denote optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 6 to 12 carbons in the ring portion, such as phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyl and substituted phenyl are the more preferred aryl.

[0100] The terms “halogen” or “halo” as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.

[0101] The term “heteroaromatic” as used herein alone or as part of another group denote optionally substituted aromatic groups having at least one carbon atom and at least heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring. The heteroaromatic group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom. Exemplary heteroaromatics include furyl, thienyl, pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl and the like. Exemplary substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.

[0102] The term “heteroatom” shall mean atoms other than carbon and hydrogen.

[0103] The terms “heterocyclo” or “heterocyclic” as used herein alone or as part of another group denote optionally substituted, fully saturated or unsaturated, monocyclic or bicyclic, aromatic or nonaromatic groups having at least one heteroatom in at least one ring, and preferably 5 or 6 atoms in each ring. The heterocyclo group preferably has 1 or 2 oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring, and may be bonded to the remainder of the molecule through a carbon or heteroatom. Exemplary heterocyclo include heteroaromatics such as furyl, thienyl, pyridyl, oxazolyl, pyrazolyl, pyrrolyl, indolyl, quinolinyl, thiazolyl, isoquinolinyl and the like. Exemplary substituents include one or more of the following groups: hydrocarbyl, substituted hydrocarbyl, keto, hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy, aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals, esters and ethers.

[0104] The terms “hydrocarbon” and “hydrocarbyl” as used herein describe organic compounds or radicals consisting exclusively of the elements carbon and hydrogen. These moieties include alkyl, alkenyl, alkynyl, and aryl moieties. These moieties also include alkyl, alkenyl, alkynyl, and aryl moieties substituted with other aliphatic, cyclic or aryl hydrocarbon groups, such as alkaryl, alkenaryl and alkynaryl. Unless otherwise indicated, these moieties preferably comprise 1 to 20 carbon atoms.

[0105] The “substituted” alkyl, alkenyl, alkynyl, aryl, hydrocarbyl or heterocyclo moieties described herein are moieties which are substituted with a hydrocarbyl moiety, a substituted hydrocarbyl moiety, a heteroatom, or a heterocyclo. For example, substituents include moieties in which a carbon atom is substituted with a hetero atom such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom. These substituents include halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, protected hydroxy, keto, acyl, acyloxy, nitro, amino, amido, nitro, cyano, thiol, ketals, acetals, esters and ethers.

[0106] The following examples illustrate the invention.

EXAMPLES 1-4

[0107] Step 1

[0108] 2-amino thiophenol was dissolved in THF. Methyl (3-bromomethyl) benzoate was added along with PS-DIEA resin and the mixture was agitated at room temperature overnight. The reaction was filtered and the filtrate was concentrated under a stream of nitrogen to afford the product.

[0109] Step 2

[0110] The product from step 1 was acylated by using excess of the appropriate acid chloride, PS-DMAP resin, PS-DIEA resin in dichloromethane and agitating the reaction overnight at room temperature. PS-Trisamine was added in and the reaction agitated a further 18 h. The reaction was filtered and the filtrate was concentrated under a stream of nitrogen to afford the product.

Example			Mass
Number	Structure	Compound Name(s)	Spec
1	13	methyl 3-[({2-[(3-chloro-2,2- dimethylpropanoyl)amino]phenyl}thio)methyl]benzoate	392.2
2	14	methyl 3-[({2-[(thien-2-yl carbonyl) amino]phenyl}thio)methyl]benzoate	384.0
3	15	methyl 3-[({2-[(trichloro acetyl) amino]phenyl}thio)methyl]benzoate	420.0
4	16	methyl 3-[({2-[(2,2-dimethyl propanoyl)amino]phenyl}thio)methyl]benzoate	358.2

EXAMPLES 5-28

[0111] Step 1

[0112] The product of Example 4 was dissolved in THF and treated with an aqueous solution of lithium hydroxide overnight. The mixture was made acidic with hydrochloric acid and then extracted with ethyl acetate. The organic layer was removed with water then saturated sodium chloride solution. The solvent was removed in vacuo and the residue recrystallized from a mix of ethyl acetate and hexane to afford colorless plates.

[0113] Step 2

[0114] The product from step 1 was dissolved in dichloromethane and treated with PS-carbodiimide resin and excess of the appropriate amine. The mixture was agitated overnight and then treated with PS-TsOH and MP-carbonate resin, agitated another 24 h filtered and the filtrate concentrated under a stream of nitrogen to afford the products.

Example			Mass
No	Structure	Compound Name(s)	Spec
5	17	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio) methyl]- N-isopentylbenzamide	413.2
6	18	3-[8 ({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-(4- methoxybenzyl)benzamide	463.2
7	19	2,2-dimethyl-N-[2-({3-[(4-methyl piperazin-1-yl)carbonyl]benzyl}thio) phenyl]propanamide	426.2
8	20	2,2-dimethyl-N-[2-({3-[(4-phenyl piperazin-1-yl)carbonyl]benzyl}thio) phenyl]propanamide
9	21	2,2-dimethyl-N-(2-{[3-(piperidin- 1-ylcarbonyl) benzyl]thio}phenyl) propanamide	411.2
10	22	N-(1,3-benzodioxol-5-yl methyl)- 3-[({2-[(2,2-dimethyl propanoyl)amino]phenyl}thio)methyl]benzamide	477.2
11	23	3-[({2-[(2,2-dimethyl propanoyl) amino]phenyl}thio)methyl]-N- phenylbenzamide	419.2
12	24	N-benzyl-3-[({2-[(2,2-dimethyl propanoyl)amino]phenyl}thio) methyl]benazmide	433.2
13	25	N-[2-({3-[(4-benzylpiperidin-1- yl)carbonyl]benzyl}thio)phenyl]- 2,2-dimethylpropanamide	501.2
14	26	N-butyl-3-[({2-[(2,2-dimethyl propanoyl)amino]phenyl}thio)me thyl]benzamide	399.2
15	27	N-cyclohexyl-3-[({2-[(2,2- dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide	425.2
16	28	3-[({2-[(2,2-dimethyl propa noyl)amino]phenyl}thio)methyl]- N-(3-fluorobenzyl)benzamide	451.2
17	29	N-(2,6-dimethoxybenzyl)-3-[({2- [(2,2-dimethylpropanoyl) amino]thio)methyl]benzamide	493.2
18	30	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-(2- furylmethyl)benzamide	423.2
19	31	methyl N-{3-[({2-[(2,2-dimethyl propanoyl)amino]phenyl}thio)me thyl]benzoyl}glycinate	415.2
20	32	methyl N-{3-[({2-[(2,2-dimethyl propanoyl)amino]phenyl}thio)me thyl]benzoyl}serinate	445.2
21	33	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]N-(tetrahydrofuran-2-ylmethyl) benzamide	427.2
22	34	N-(2,3-dimethoxybenzyl)-3-[({2- [(2,2-dimethylpropanoyl) benzamide	493.2
23	35	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-(2- ethoxybenzyl)benzamide	477.2
24	36	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-(4- fluorobenzyl)benzamide	451.2
25	37	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-(2- methoxybenzyl)benzamide	463.2
26	38	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-(3- methoxybenzyl)benzamide	463.2
27	39	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N-[4- (trifluoromethoxy)benzyl]benzamide	517.2
28	40	3-[({2-[(2,2-dimethylpropanoyl) amino]phenyl}thio)methyl]-N- (3,4,5-trimethoxybenzyl) benzamide	523.2
29	41	N-(3,4-dimethoxybenzyl)-3-[({2- [(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide	493.2
30	42	N-(2,4-dimethoxybenzyl)-3-[({2- [(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide	493.2

EXAMPLES 31-38

[0115] Step 1

[0116] 2-amino thiophenol was dissolved in THF. Methyl (3-bromomethyl) benzoate was added along with PS-DIEA resin and the mixture was agitated at room temperature overnight. The reaction was filtered and the filtrate was concentrated under a stream of nitrogen to afford the product.

[0117] Step 2

[0118] The product of step 1 was dissolved in THF and treated with an aqueous solution of lithium hydroxide overnight. The mixture was made neutral with hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with water and then with saturated sodium chloride solution. The solvent was removed in vacuo to afford the product.

[0119] Step 3

[0120] The product from step 2 was dissolved in dichloromethane and treated with PS-carbodiimide resin and the appropriate amine. The mixture was agitated overnight and then treated with MP-carbonate resin, agitated another 24 h filtered and the filtrate concentrated under a stream of nitrogen to afford the products.

[0121] Step 4

[0122] The product from step 3 was acylated by using excess of the appropriate acid chloride, PS-DMAP resin, PS-DIEA resin in dichloromethane and agitating the reaction overnight at room temperature. PS-Trisamine was added in and the reaction agitated a further 18 h. The reaction was filtered and the filtrate was concentrated under a stream of nitrogen to afford the product.

Example			Mass
No	Structure	Compound Name(s)	Spec
31	43	N-{2-[(3-{[(2,4-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phenyl}pyridine-2-carboxamide	514.2
32	44	N-{2-[(3-{[(2,6-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}pyridine-2-carboxamide	514.2
33	45	2-({2-[(3-{[(2,4-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}amino)-2-oxoethyl acetate	509.2
34	46	3-[({2-[(3-{[(2,4- dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}amino)carbonyl]-2- methylphenyl acetate	585.2
35	47	2-({2-[(3-{[(2,4-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}amino)-1-methyl-2-oxoethyl acetate	523.2
36	48	2-({2-[(3-{[(2,4-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}amino)-2-oxo-1-phenylethyl acetate	585.2
37	49	N-{2-[(3-{[(2,4-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}-2-methoxybenzamide	543.2
38	50	N-{2-[(3-{[(2,4-dimethoxybenzyl) amino]carbonyl}benzyl)thio]phen yl}nicotinamide	514.2

EXAMPLES 39-41

[0123] Step 1

[0124] 2-amino thiophenol was dissolved in THF. Methyl (3-bromomethyl) benzoate was added along with PS-DIEA resin and the mixture was agitated at room temperature overnight. The reaction was filtered and the filtrate was removed under a stream of Nitrogen to afford the product.

[0125] Step 2

[0126] The product of step 1 was dissolved in THF and treated with an aqueous solution of lithium hydroxide overnight. The mixture was made neutral with hydrochloric acid and then extracted with ethyl acetate. The organic layer was washed with water then saturated sodium chloride solution. The solvent was removed in vacuo to afford the product.

[0127] Step 3

[0128] The product from step 2 was dissolved in dichloromethane and treated with PS-carbodiimide resin and the appropriate amine. The mixture was agitated overnight and then treated with MP-carbonate resin, agitated another 24 h filtered and the filtrate concentrated under a stream of nitrogen to afford the products.

[0129] Step 4

[0130] The product from step 3 was then acylated by using excess of chloromethyl acetyl chloride, PS-DMAP resin, PS-DIEA in dichloromethane and agitating the reaction overnight at room temperature. The reaction was filtered and the filtrate was reduced under a stream of nitrogen to afford the product.

[0131] Step 5

[0132] The product of step 4 was combined in dichloromethane (2.5 mL) with an excess of the appropriate amine and DIEA resin (4 equivalents). The reaction was subjected to microwave heating for 25 minutes at 100 degrees filtered and the residue chromatographed on silica to give the title product.

EXAMPLES 39-41

[0133]

Example			Mass
No	Structure	Compound Name(s)	Spec
39	51	N-(2,4-dimethoxybenzyl)-3-{[(2- {[N-(2-methoxyethyl)glycyl]amino}phenyl)thio]methyl}benzamide	524.2
40	52	N-(2,4-dimethoxybenzyl)-3-[({2- [(piperidin-1-ylacetyl)amino]phenyl}thio)methyl]benzamide	534.2
41	53	N-(2,4-dimethoxybenzyl)-3-{[(2- {[N-(tetrahydrofuran-2-ylmethyl) glycyl]amino}phenyl)thio]methyl}benzamide	550.2

EXAMPLE 42

[0134] N-(2,4-dimethoxybenzyl)-3-[({3-[(2,2-dimethylpropanoyl)amino]pyridin-2-yl}thio)methyl] benzamide 54

[0135] Step 1

[0136] 3-chloromethylbenzoic acid (5.9 mmol) was dissolved in DMF and carbonyldiimidazole (6.2 mmol) added. After 5 minutes the amine (5.8 mmol) was added and the reaction stirred at room temperature for 4 h. The reaction mixture was diluted with water and extracted with dichloromethane. The combined organics were dried over MgSO4, filtered, and the solvent removed. The crude residue was purified by flash chromatography.

[0137] Step 2

[0138] The product from step 1 (1.6 mmol) was dissolved in DMF along with the nitrothiopyridine (1.6 mmol). To this solution was added Hunig's base (3.1 mmol) and the reaction stirred at room temperature overnight. The reaction mixture was treated with acetic acid solution and the product extracted with dichloromethane. The combined organics were dried over MgSO4, filtered, and the solvent removed. The crude residue was purified by flash chromatography.

[0139] Step 3

[0140] The product from step 2 (0.36 mmol) was dissolved in ethanol and tin chloride dihydrate added. The reaction mixture was heated at 70° C for 2 h. The residue was diluted with water and the product extracted with DCM. The combined organics were dried over MgSO4, filtered, and the solvent removed. The crude product was used in the next reaction.

[0141] Step 4

[0142] The product from step 3 (0.07 mmol) was dissolved in DCM and the acid chloride (0.08 mmol) added. To this was added PS-DIEA and PS-DMAP and the reaction stirred at RT overnight. The crude product was filtered and the solvent removed. The product was purified by flash chromatography.

EXAMPLES 43-54

[0143]

Example			Formula
No	Structure	Compound Name(s)	weight
43	55	3-[({2-[(cyclopentylcarbonyl) amino]phenyl}thio)methyl]-N-(2,4- dimethoxybenzyl)benzamide	504.65
44	56	N-(2,4-dimethoxybenzyl)-3-{[(2-{[(1- phenylcyclopropyl)carbonyl]amino}phenyl)thio]methyl}benzamide	552.7
45	57	3-({[2-({[1-(4- chlorophenyl)cyclopentyl]carbonyl}amino)phenyl]thio}methyl)-N-(2,4- dimethoxybenzyl)benzamide	615.2
46	58	6-chloro-N-{2-[(3-{[(2,4-dimethoxy benzyl)amino]carbonyl}benzylthio]phenyl}nicotinamide	548.07
47	59	6-chloro-N-{2-[(3-{[(2,6-dimethoxy benzyl)amino]carbonyl}benzyl)thio]phenyl}nicotinamide	548.07
48	60	3-({2-[(3-chloro-2,2-dimethyl propanoyl)amino]benzyl}thio)-N- (2,4-dimethoxybenzyl)benzamide	527.09
49	61	3-({2-[(cyclopentylcarbonyl)amino]benzyl}thio)-N-(2,4-dimethoxy benzyl)benzamide	504.65
50	62	3-({2-[(3-chloro-2,2-dimethyl propanoyl)amino]benzyl}thio)-N- (2,6-dimethoxybenzyl)benzamide	527.09
51	63	3-({2-[(cyclopentylcarbonyl) amino]benzyl}thio)-N-(2,6- dimethoxybenzyl)benzamide	504.65
52	64	N-(2,6-dimethoxybenzyl)-3-({2-[(2,2- dimethylpropanoyl)amino]benzyl}thio)benzamide	492.64
53	65	N-(2,6-dimethoxybenzyl)-3-({2- [(trichloroacetyl)amino]benzyl}thio)b enzamide	553.9
54	66	N-(2,6-dimethoxybenzyl)-3-({2-[(3,3- dimethylbutanoyl)amino]benzyl}thio) benzamide	506.67

EXAMPLE 55

[0144] LXR Reporter Gene Transactivation Assay for High-Throughput Screen

[0145] Human hepatic cells (Huh-7) were cotransfected with a luciferase reporter gene (pGal4-RE), where transcription of luciferase gene is driven by the Gal4 response element, and a chimeric gene construct of liver X receptor (Gal4DBD-LXRαLBD), which comprises a DNA sequence that encodes a hybrid protein of LXR ligand binding domain (LXRLBD) and Gal4 DNA-binding domain (Gal4DBD). The transfection was performed in culture dishes using LipofectAMINE2000 reagent. The transfected cells were harvested 20 hr later and resuspended in assay medium containing RPMI 1640 medium, 2% fetal bovine lipoprotein deficient serum, 100 units/ml pencillin and 100 μg/ml streptomycin.

[0146] In screening for LXR modulators, the transfected cells were dispensed in an assay plate (384-well white tissue culture plate) containing the test compounds at 10 μM final concentration and incubated for 24 hr. The effects of test compounds on the activation of LXRLBD and hence luciferase transcription was determined by measuring the luciferase activity using Steady-Glo luciferase assay substrate. Luciferase activity results are expressed as the fold-induction relative to DMSO controls. Compounds that exhibited >10 fold induction were then retested and the EC50 was determined as the concentration necessary to produce 50% of the maximal luciferase activity. Each of the compounds of Examples 1-54 was found to have an EC50 of less than 50 μM.

Claims

1. A compound corresponding to Formula I and the isomers, tautomers, salts and prodrugs thereof:

2. The compound of claim 1 wherein the sum of p and q is 1.

3. The compound of claim 1 wherein X50 is carbon and X51 is oxygen.

4. The compound of claim 1 wherein X53 is heterocyclo, optionally substituted alkyl, or optionally substituted phenyl.

5. The compound of claim 1 wherein X11, X22, X33, and X44 are hydrogen.

6. The compound of claim 2 wherein each of X1-X4 and M1-M5 is carbon.

7. A compound corresponding to Formula IV and the isomers, tautomers, salts and prodrugs thereof:

8. A compound corresponding to Formula V and the isomers, tautomers, salts and prodrugs thereof:

9. A compound corresponding to Formula VI and the isomers, tautomers, salts and prodrugs thereof:

10. The compound of claim 9 wherein M19 is methylene.

11. The compound of claim 9 wherein M20 is hydrogen.

12. The compound of claim 9 wherein X53 is heterocyclo, optionally substituted alkyl, or optionally substituted phenyl.

13. The compound of claim 9 wherein M19 is methylene; at least one of M20, M34 and M35 is alkoxy, nitro, or halo; one of X25, X26, is hydrogen and the other is an optionally substituted alkyl, nitro, or halo; and Y1-Y5 are carbon.

14. The compound of claim 9 wherein M19 is methylene; X25, X26, M20, M34 and M35 are hydrogen; and Y1-Y5 are carbon.

15. The compound of claim 14 wherein any two of Y11, Y33, and Y55 are alkoxy.

16. The compound of claim 15 wherein the alkoxy is methoxy.

17. A compound corresponding to Formula VII and the isomers, tautomers, salts and prodrugs thereof:

18. A compound corresponding to Formula VIII and the isomers, tautomers, salts and prodrugs thereof:

19. The compound of claim 18 wherein the sum of p and q is 1.

20. The compound of claim 18 wherein X53 is heterocyclo, optionally substituted alkyl, or optionally substituted phenyl.

21. The compound of claim 18 wherein one of X25 and X26 is an optionally substituted alkyl, nitro or halo, and the other is hydrogen.

22. The compound of claim 18 wherein X25, X26, M34 and M35 are hydrogen.

23. A compound corresponding to Formula IX and the isomers, tautomers, salts and prodrugs thereof:

24. The compound of claim 23 wherein the sum of p and q is 1.

25. The compound of claim 23 wherein one of X25 and X26 is an optionally substituted alkyl, nitro or halo, and the other is hydrogen.

26. The compound of claim 23 wherein X25, X26, M34 and M35 are hydrogen; and M40 is methyl.

27. A compound selected from the group consisting of methyl 3-[({2-[(3-chloro-2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzoate; methyl 3-[({2-[(thien-2-ylcarbonyl)amino]phenyl}thio)methyl]benzoate; methyl 3-[({2-[(trichloroacetyl)amino]phenyl}thio)methyl]benzoate; methyl 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzoate; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-isopentyl benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(4-methoxy benzyl) benzamide; 2,2-dimethyl-N-[2-({3-[(4-methylpiperazin-1-yl)carbonyl]benzyl}thio)phenyl]propanamide; 2,2-dimethyl-N-[2-({3-[(4-phenylpiperazin-1-yl)carbonyl]benzyl}thio)phenyl]propanamide; 2,2-dimethyl-N-(2-{[3-(piperidin-1-ylcarbonyl)benzyl]thio}phenyl) propanamide; N-(1,3-benzodioxol-5-ylmethyl)-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-phenyl benzamide; N-benzyl-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; N-[2-({3-[(4-benzylpiperidin-1-yl)carbonyl]benzyl}thio)phenyl]-2,2-dimethylpropanamide; N-butyl-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; N-cyclohexyl-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(3-fluoro benzyl)benzamide; N-(2,6-dimethoxybenzyl)-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio) methyl]benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(2-furylmethyl) benzamide; methyl N-{3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzoyl}glycinate; methyl N-{3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzoyl}serinate; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(tetrahydro furan-2-ylmethyl)benzamide; N-(2,3-dimethoxybenzyl)-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(2-ethoxy benzyl)benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(4-fluoro benzyl)benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(2-methoxy benzyl)benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(3-methoxy benzyl)benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-[4-(trifluoro methoxy)benzyl]benzamide; 3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]-N-(3,4,5-trimethoxybenzyl)benzamide; N-(3,4-dimethoxybenzyl)-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; N-(2,4-dimethoxybenzyl)-3-[({2-[(2,2-dimethylpropanoyl)amino]phenyl}thio)methyl]benzamide; N-{2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl}pyridine-2-carboxamide; N-{2-[(3-{[(2,6-dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl}pyridine-2-carboxamide; 2-({2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl}amino)-2-oxoethylacetate; 3-[({2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzyl)thiophenyl}amino)carbonyl]-2-methylphenyl acetate; 2-({2-[(3-{[(2,4dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl}amino) -1-methyl-2-oxoethyl acetate; 2-({2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl amino)-2-oxo-1-phenylethyl acetate; N-{2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl}-2-methoxybenzamide; N-{2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzyl)thio]phenyl}nicotinamide; N-(2,4-dimethoxybenzyl)-3-{[(2-{[N-(2methoxyethyl)glycyl]amino}phenyl)thio]methyl}benzamide; N-(2,4-dimethoxybenzyl)-3-[({2-[(piperidin-1-ylacetyl)amino]phenyl}thio) methyl]benzamide; N-(2,4-dimethoxybenzyl)-3-{[(2-{[N-(tetrahydrofuran-2-ylmethyl)glycyl]amino}phenyl)thio]methyl}benzamide; N-(2,4-dimethoxybenzyl)-3-[({3-[(2,2-dimethylpropanoyl)amino]pyridin-2-yl}thio)methyl]benzamide; 3-[({2-[(cyclopentylcarbonyl)amino]phenyl}thio)methyl]-N-(2,4-dimethoxybenzyl)benzamide; N-(2,4-dimethoxybenzyl)-3-{[(2-{[(1-phenylcyclopropyl)carbonyl]amino}phenyl)thio]methyl}benzamide; 3-({[2-({[1-(4-chlorophenyl)cyclopentyl]carbonyl}amino)phenyl]thio}methyl)-N-(2,4-dimethoxybenzyl)benzamide; 6-chloro-N-{2-[(3-{[(2,4-dimethoxybenzyl)amino]carbonyl}benzylthio]phenyl}nicotinamide; 6-chloro-N-{2-[(3-{[(2,6-dimethoxybenzyl)amino]carbonyl}benzyl) thio]phenyl}nicotinamide; 3-({2-[(3-chloro-2,2-dimethylpropanoyl)amino]benzyl}thio)-N-(2,4-dimethoxybenzyl)benzamide; 3-({2-[(cyclopentylcarbonyl)amino]benzyl}thio)-N-(2,4-dimethoxy benzyl)benzamide; N-(2,4-dimethoxybenzyl)-3-({2-[(2,2-dimethylpropanoyl)amino]benzyl}thio)benzamide; 3-({2-[(3-chloro-2,2-dimethylpropanoyl)amino]benzyl}thio)-N-(2,6-dimethoxybenzyl)benzamide; 3-({2-[(cyclopentylcarbonyl)amino]benzyl}thio)-N-(2,6-dimethoxybenzyl) benzamide; N-(2,6-dimethoxybenzyl)-3-({2-[(2,2-dimethylpropanoyl)amino]benzyl}thio)benzamide; N-(2,6-dimethoxybenzyl)-3-({2-[(trichloroacetyl)amino]benzyl}thio) benzamide; N-(2,6-dimethoxybenzyl)-3-({2-[(3,3-dimethylbutanoyl)amino]benzyl}thio) benzamide.

28. A process for the treatment or prevention of a condition in a mammal which is modulated by LXR, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound according to claim 1.

29. A process for the treatment or prevention of a condition in a mammal which is modulated by LXR, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound according to claim 9.

30. A process for the treatment or prevention of a condition in a mammal which is modulated by LXR, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound according to claim 27.